ReVeRa-201
Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray for the Reduction of Ventricular Rate in Patients with Atrial Fibrillation
- Stadium
- klaar
- Middel
- Etripamil
- Populatie
- Ritme
- Fase
- II
- First Patient In
- 6 februari 2023
- Last Patient In
- 4 augustus 2023
- Last Patient Last Visit
- 31 december 2023
National Lead
dr. A.M.W. Alings
Cardioloog
Studiedirecteur
dr. M.E.W. Hemels
Cardioloog
Contact Kantoor
